<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Opthea Ltd — News on 6ix</title>
<link>https://6ix.com/company/opthea-ltd</link>
<description>Latest news and press releases for Opthea Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 02 Mar 2026 02:35:13 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/opthea-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836689278dffbe2df15ec69.webp</url>
<title>Opthea Ltd</title>
<link>https://6ix.com/company/opthea-ltd</link>
</image>
<item>
<title>Appendix 4D and Half Year Report for period 31 Dec 2025</title>
<link>https://6ix.com/company/opthea-ltd/news/appendix-4d-and-half-year-report-for-period-31-dec-2025</link>
<guid isPermaLink="true">https://6ix.com/company/opthea-ltd/news/appendix-4d-and-half-year-report-for-period-31-dec-2025</guid>
<pubDate>Mon, 02 Mar 2026 02:35:13 GMT</pubDate>
<description>Appendix 4D and Half Year Report for period 31 Dec 2025</description>
</item>
<item>
<title>Quarterly Activities/Appendix 4C Cash Flow Report</title>
<link>https://6ix.com/company/opthea-ltd/news/quarterly-activitiesappendix-4c-cash-flow-report-14</link>
<guid isPermaLink="true">https://6ix.com/company/opthea-ltd/news/quarterly-activitiesappendix-4c-cash-flow-report-14</guid>
<pubDate>Fri, 30 Jan 2026 03:34:25 GMT</pubDate>
<description>Quarterly Activities/Appendix 4C Cash Flow Report</description>
</item>
<item>
<title>Long Term Suspended Entities</title>
<link>https://6ix.com/company/opthea-ltd/news/long-term-suspended-entities-1</link>
<guid isPermaLink="true">https://6ix.com/company/opthea-ltd/news/long-term-suspended-entities-1</guid>
<pubDate>Thu, 22 Jan 2026 10:51:04 GMT</pubDate>
<description>Long Term Suspended Entities</description>
</item>
<item>
<title>Investor Update Presentation</title>
<link>https://6ix.com/company/opthea-ltd/news/investor-update-presentation-2</link>
<guid isPermaLink="true">https://6ix.com/company/opthea-ltd/news/investor-update-presentation-2</guid>
<pubDate>Wed, 17 Dec 2025 04:23:09 GMT</pubDate>
<description>Investor Update Presentation</description>
</item>
<item>
<title>Opthea Receives A$10.8 million R&D Tax Incentive</title>
<link>https://6ix.com/company/opthea-ltd/news/opthea-receives-adollar108-million-randd-tax-incentive</link>
<guid isPermaLink="true">https://6ix.com/company/opthea-ltd/news/opthea-receives-adollar108-million-randd-tax-incentive</guid>
<pubDate>Mon, 06 Oct 2025 01:57:14 GMT</pubDate>
<description>Opthea Receives A$10.8 million R&D Tax Incentive</description>
</item>
<item>
<title>S&P DJI Announces September 2025 Quarterly Rebalance</title>
<link>https://6ix.com/company/opthea-ltd/news/sandp-dji-announces-september-2025-quarterly-rebalance-38</link>
<guid isPermaLink="true">https://6ix.com/company/opthea-ltd/news/sandp-dji-announces-september-2025-quarterly-rebalance-38</guid>
<pubDate>Fri, 05 Sep 2025 11:30:10 GMT</pubDate>
<description>S&P DJI Announces September 2025 Quarterly Rebalance</description>
</item>
<item>
<title>Preliminary Final Report</title>
<link>https://6ix.com/company/opthea-ltd/news/preliminary-final-report-58</link>
<guid isPermaLink="true">https://6ix.com/company/opthea-ltd/news/preliminary-final-report-58</guid>
<pubDate>Fri, 29 Aug 2025 13:37:15 GMT</pubDate>
<description>Preliminary Final Report</description>
</item>
<item>
<title>Corporate Update Investor Call</title>
<link>https://6ix.com/company/opthea-ltd/news/corporate-update-investor-call</link>
<guid isPermaLink="true">https://6ix.com/company/opthea-ltd/news/corporate-update-investor-call</guid>
<pubDate>Wed, 20 Aug 2025 03:23:33 GMT</pubDate>
<description>Corporate Update Investor Call</description>
</item>
<item>
<title>Opthea Provides Corporate Update</title>
<link>https://6ix.com/company/opthea-ltd/news/opthea-provides-corporate-230000982</link>
<guid isPermaLink="true">https://6ix.com/company/opthea-ltd/news/opthea-provides-corporate-230000982</guid>
<pubDate>Mon, 18 Aug 2025 23:00:00 GMT</pubDate>
<description>Successful DFA settlement reached Company with cash and cash equivalents of approximately USD20M Dr Fred Guerard, CEO, Tom Reilly, CFO, and Sujal Shah, Director, to step down Dr Jeremy Levin to continue as Chairman and to assume additional responsibilities as of September 1st MELBOURNE, Australia and PRINCETON, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), today provided a corporate update following the successful settlement of the Development</description>
</item>
<item>
<title>Continuation of Suspension from Quotation</title>
<link>https://6ix.com/company/opthea-ltd/news/continuation-of-suspension-from-quotation-3</link>
<guid isPermaLink="true">https://6ix.com/company/opthea-ltd/news/continuation-of-suspension-from-quotation-3</guid>
<pubDate>Mon, 31 Mar 2025 06:05:08 GMT</pubDate>
<description>Continuation of Suspension from Quotation</description>
</item>
<item>
<title>Opthea Announces Decision to Discontinue Wet AMD Trials</title>
<link>https://6ix.com/company/opthea-ltd/news/opthea-announces-decision-discontinue-wet-040100489</link>
<guid isPermaLink="true">https://6ix.com/company/opthea-ltd/news/opthea-announces-decision-discontinue-wet-040100489</guid>
<pubDate>Mon, 31 Mar 2025 04:01:00 GMT</pubDate>
<description>ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea and DFA Investors agreed to terminate both COAST and ShORe trials Opthea continues to consider impact of negative trial results under its Development Funding Agreement (DFA) and on the Company as a going concern MELBOURNE, Australia and PRINCETON, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage b</description>
</item>
<item>
<title>Opthea Announces COAST Phase 3 Trial Topline Results</title>
<link>https://6ix.com/company/opthea-ltd/news/opthea-announces-coast-phase-3-040100859</link>
<guid isPermaLink="true">https://6ix.com/company/opthea-ltd/news/opthea-announces-coast-phase-3-040100859</guid>
<pubDate>Mon, 24 Mar 2025 04:01:00 GMT</pubDate>
<description>COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on the Company as a going concern MELBOURNE, Australia and PRINCETON, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, incl</description>
</item>
<item>
<title>Voluntary suspension</title>
<link>https://6ix.com/company/opthea-ltd/news/voluntary-suspension-7</link>
<guid isPermaLink="true">https://6ix.com/company/opthea-ltd/news/voluntary-suspension-7</guid>
<pubDate>Wed, 19 Mar 2025 02:57:25 GMT</pubDate>
<description>Voluntary suspension</description>
</item>
<item>
<title>Trading Halt</title>
<link>https://6ix.com/company/opthea-ltd/news/trading-halt-201</link>
<guid isPermaLink="true">https://6ix.com/company/opthea-ltd/news/trading-halt-201</guid>
<pubDate>Mon, 17 Mar 2025 02:02:18 GMT</pubDate>
<description>Trading Halt</description>
</item>
<item>
<title>Opthea Announces Phase 2b Wet AMD Publication</title>
<link>https://6ix.com/company/opthea-ltd/news/opthea-announces-phase-2b-wet-120000295</link>
<guid isPermaLink="true">https://6ix.com/company/opthea-ltd/news/opthea-announces-phase-2b-wet-120000295</guid>
<pubDate>Mon, 03 Mar 2025 12:00:00 GMT</pubDate>
<description>Baseline angiographic lesion characteristics predictive of clinical response Published in peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina MELBOURNE, Australia and PRINCETON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the</description>
</item>
<item>
<title>Opthea Reports Half Year Results and Business Updates</title>
<link>https://6ix.com/company/opthea-ltd/news/opthea-reports-half-results-business-120000258</link>
<guid isPermaLink="true">https://6ix.com/company/opthea-ltd/news/opthea-reports-half-results-business-120000258</guid>
<pubDate>Fri, 28 Feb 2025 12:00:00 GMT</pubDate>
<description>Cash and cash equivalents of $131.9M as of December 31, 2024 Cash runway extends through anticipated topline data readouts of COAST (early 2Q CY25) and ShORe (mid-CY25) MELBOURNE, Australia and PRINCETON, N.J., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today an</description>
</item>
<item>
<title>Opthea Half Year Financial Report - Appendix 4D</title>
<link>https://6ix.com/company/opthea-ltd/news/opthea-half-year-financial-report-appendix-4d</link>
<guid isPermaLink="true">https://6ix.com/company/opthea-ltd/news/opthea-half-year-financial-report-appendix-4d</guid>
<pubDate>Fri, 28 Feb 2025 02:42:25 GMT</pubDate>
<description>Opthea Half Year Financial Report - Appendix 4D</description>
</item>
<item>
<title>Opthea Completes Drug Product PPQ Campaign</title>
<link>https://6ix.com/company/opthea-ltd/news/opthea-completes-drug-product-ppq-120000914</link>
<guid isPermaLink="true">https://6ix.com/company/opthea-ltd/news/opthea-completes-drug-product-ppq-120000914</guid>
<pubDate>Wed, 26 Feb 2025 12:00:00 GMT</pubDate>
<description>Three consecutive commercial-scale drug product batches successfully produced Supports potential sozinibercept BLA filing in 1H CY2026 MELBOURNE, Australia and PRINCETON, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the completion of its drug</description>
</item>
<item>
<title>Opthea Completes COAST Final Week 52 Patient Visit</title>
<link>https://6ix.com/company/opthea-ltd/news/opthea-completes-coast-final-week-120000572</link>
<guid isPermaLink="true">https://6ix.com/company/opthea-ltd/news/opthea-completes-coast-final-week-120000572</guid>
<pubDate>Tue, 18 Feb 2025 12:00:00 GMT</pubDate>
<description>COAST Phase 3 trial evaluates superiority and safety of sozinibercept combined with aflibercept in wet AMD Company confirms topline results for COAST anticipated in early 2Q CY25 MELBOURNE, Australia and PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD),</description>
</item>
<item>
<title>Opthea Investor Day</title>
<link>https://6ix.com/company/opthea-ltd/news/opthea-investor-day</link>
<guid isPermaLink="true">https://6ix.com/company/opthea-ltd/news/opthea-investor-day</guid>
<pubDate>Wed, 29 Jan 2025 02:35:16 GMT</pubDate>
<description>Opthea Investor Day</description>
</item>
</channel>
</rss>